The NMHPVPR monitors the complete continuum of cervical cancer prevention in New Mexico and Is the only population-based, woman-based, cervical screening registry In the U.S. Using clinically relevant electronic medical records (EMR), detailed woman-based information including text dictations is generated for cervical cancer screening, diagnosis and treatment delivered throughout New Mexico. All results of tests whether positive or negative, normal or abnormal are transmitted to the NMHPVPR under state mandate. This unique public health resource serves as the cornerstone of the NM-HOPES-PRC Cervical Cancer Screening Process Documentation Unit. The NMHPVPR information systems, which are fully electronic, transcend organizational structures of healthcare. Reporting to the NMHPVPR is conducted at a national, regional and statewide level and is based at the individual woman and provider levels. By comparison to organizational systems such as Managed Care Organizations (MCO), which suffer both loss from area out-migration and loss to membership due to personal decisions or changes in employer insurance agreements, the NMHPVPR only suffers out-migration from the entire state of New Mexico. New Mexico incurs and average outmigration by comparison to other states, it is 27th In the nation. The NMHPVPR embodies the entire spectrum of clinical practice delivery of cervical cancer prevention Including Indian Health Service Facilities, an MCO, multiple health plans, community-based practice networks and Individual provider practices in largely isolated areas of the state. The annual woman-based data contributions from the NMHOPES from the entire state of New Mexico represent ~225,000 cervical cancer screening Pap events (plus abnormal referral Paps) and an average of over 18,000 diagnostic colposcopy and LEEP treatment visits including clinic visits with cervical, vaginal, vulvar or endometrial biopsy procedures. Beyond the innovations of the NMHPVPR, in anticipation of PROSPR directions and needs, we have engaged specific partnerships with a number of clinic networks who deliver care to the underserved and impoverished Hispanic and American Indian women of our state who are at high risk for invasive cervical cancer. In our selected clinical provider network partnerships, over 30,000 screening Pap tests are delivered each year and over 40,000 individual women screen in a 3-year period versus an estimated 57,000 screen-eligible women. Based on the HEDIS quality measures for cervical cancer (i.e., PAP testing within the measurement year or prior 2 years), our partnering practices deliver cervical cancer screening at varying levels ranging from 68%-72% of their screen-eligible patients. We have specifically partnered with a range of clinical settings to provide broad opportunities to the PROSPR Consortium. Our research projects target gaps in knowledge to enable future interventions to improve cervical cancer prevention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA164336-04
Application #
8729299
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2014-06-01
Project End
2016-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
4
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of New Mexico Health Sciences Center
Department
Type
DUNS #
City
Albuquerque
State
NM
Country
United States
Zip Code
Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2018) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 27:158-164
Kamineni, Aruna; Tiro, Jasmin A; Beaber, Elisabeth F et al. (2018) Cervical cancer screening research in the PROSPR I consortium: Rationale, methods and baseline findings from a US cohort. Int J Cancer :
Doubeni, Chyke A; Gabler, Nicole B; Wheeler, Cosette M et al. (2018) Timely follow-up of positive cancer screening results: A systematic review and recommendations from the PROSPR Consortium. CA Cancer J Clin 68:199-216
Castle, Philip E; Wheeler, Cosette M; Campos, Nicole G et al. (2018) Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. Prev Med 111:177-179
McDonald, Yolanda J; Schwind, Michael; Goldberg, Daniel W et al. (2017) An analysis of the process and results of manual geocode correction. Geospat Health 12:526
Cuzick, Jack; Myers, Orrin; Lee, Ji-Hyun et al. (2017) Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing. JAMA Oncol 3:1327-1334
McDonald, Yolanda J; Goldberg, Daniel W; Scarinci, Isabel C et al. (2017) Health Service Accessibility and Risk in Cervical Cancer Prevention: Comparing Rural Versus Nonrural Residence in New Mexico. J Rural Health 33:382-392
McCarthy, Anne Marie; Kim, Jane J; Beaber, Elisabeth F et al. (2016) Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity. Am J Prev Med 51:507-12
Gage, Julia C; Hunt, William C; Schiffman, Mark et al. (2016) Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines. Obstet Gynecol 128:1248-1257
Corley, Douglas A; Haas, Jennifer S; Kobrin, Sarah (2016) Reducing Variation in the ""Standard of Care"" for Cancer Screening: Recommendations From the PROSPR Consortium. JAMA 315:2067-8

Showing the most recent 10 out of 31 publications